Is Alumis Inc. (ALMS) a Buy, Sell, or Hold?
NASDAQ : ALMS
Alumis Inc.
$27.08 USD
-$0.92 (-3.29%)
- Volume
- 1.02M
- Average Volume
- 1.31M
- Market Capitalization
- $3.34B
- P/E Ratio
- -14.18
- Dividend Yield
- 0.00%
- Price Target
- $39.50
- Year High
- $31.35
- Year Low
- $3.75
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.51
Company Overview
NASDAQ
Martin Babler
Biotechnology
Healthcare
ALMS
223
US
USD
Liquidity Metrics
0.06
7.51
7.51
0.90
0.00
Sales & Valuation
$24.05M
397.83
5.97
-8.87
-3.02
Profitability
-$2.32
-$243.32M
-2825.70%
-2927.59%
-54.63%
-35.35%
P/E Metrics
-14.18
-0.10
-0.10
Analyst Price Target & Rating
$39.50
$51.00
$25.00
2/5
8 Analysts
-31.44%
Financial Health Scores
16.54
1/9
$461.5M
$671.59M
$104.57M
-$417.58M
Key Metrics (TTM)
$3.43B
407.98
-8.28
7.51
-54.63%
-71.89%
-6.78%
-10.91%
-4737 days
Company Executives
| Name | Title |
|---|---|
| Sanam Pangali | Chief Legal Officer & Corporate Secretary |
| John R. Schroer | Chief Financial Officer |
| Mark Bradley | Chief Development Officer |
| Jorn Drappa | Chief Medical Officer & Head of Research and Development |
| Roy C. Hardiman | Chief Business & Strategy Officer |
| Kolbot By | Senior Vice President & Head of Technical Operations |
| Philip Nunn | Senior Vice President of Pharmacology & Project Team Leader |
| Claire Langrish | Senior Vice President & Head of Immunology and Translational Science |
| David Goldstein | Chief Scientific Officer |
| Martin Babler | President, Chief Executive Officer & Chairman |
Poll Results
No votes yet today — be the first to share your view!
About Alumis Inc. (NASDAQ:ALMS) Stock
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquar ... tered in South San Francisco, California.
Alumis (NASDAQ:ALMS) Shares Up 5.7% – What’s Next?
2026-07-19 04:01:42
Alumis Inc. (NASDAQ: ALMS - Get Free Report)'s share price was up 5.7% on Friday. The company traded as high as $28.64 and last traded at $28.78. 295,097 shares traded hands during trading, a decline of 86% from the average daily volume of 2,138,687 shares. The stock had previously closed at $27.23. Wall Street Analysts
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon
2026-06-25 17:58:44
Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeucitinib in psoriasis and SLE. Phase 3 data for envudeucitinib showed strong efficacy and safety, though not outright superiority versus competitors, and twice-daily dosing is a minor drawback. Upcoming 2026 catalysts include long-term psoriasis data, NDA submission, and pivotal SLE data, all critical for valuation and acquisition potential.
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
2026-05-24 10:13:59
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
2026-05-17 14:13:40
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
2026-05-15 18:36:41
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
2026-05-14 16:05:00
– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms –
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
2026-05-10 05:33:01
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Frequently Asked Questions
-
What is the current Alumis Inc. (ALMS) stock price?
-
Alumis Inc.(NASDAQ:ALMS) stock price is $27.08 in the last trading session. During the trading session, ALMS stock reached the peak price of $31.35 while $3.75 was the lowest point it dropped to. The percentage change in ALMS stock occurred in the recent session was --3.29% while the dollar amount for the price change in ALMS stock was -$0.92.
-
ALMS's industry and sector of operation?
-
The NASDAQ listed ALMS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALMS?
-
Sanam Pangali | Chief Legal Officer & Corporate Secretary
John R. Schroer | Chief Financial Officer
Mark Bradley | Chief Development Officer
Jorn Drappa | Chief Medical Officer & Head of Research and Development
Roy C. Hardiman | Chief Business & Strategy Officer -
How many employees does ALMS have?
-
Number of ALMS employees currently stands at 223. ALMS operates from 280 East Grand Avenue, South San Francisco, CA 94080, US.
-
Link for ALMS official website?
-
Official Website of ALMS is: https://www.alumis.com
-
How do I contact ALMS?
-
ALMS could be contacted at phone #(650) 231-6625 and can also be accessed through its website. ALMS operates from 280 East Grand Avenue, South San Francisco, CA 94080, US.
-
How many shares of ALMS are traded daily?
-
The average number of ALMS shares traded daily for last 3 months was 1.31M.
-
What is the market cap of ALMS currently?
-
The market value of ALMS currently stands at $3.34B with its latest stock price at $27.08